NUTH, The Netherlands and SAN DIEGO, Aug. 07, 2017 -- Fortimedix Surgical today announced the official U.S. launch of its product line extension with symphonX™ Instruments short. The new product line offers shorter instruments that broaden surgical applicability of the symphonX™ Surgical Platform, further increasing the ease of use for surgeons during specific surgical procedures.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba3500cd-9477-42ff-a33c-8292466f85b3
symphonX™ is the world’s lowest profile single-port surgery solution for use in minimally invasive abdominal laparoscopic surgery. The symphonX™ Instruments portfolio includes various products for grasping, mobilizing, dissecting, retracting, cutting, cauterizing, ligating, and suction/irrigation of tissues and vessels. With this line extension, these different types of instruments are available in a short version. Choosing the appropriate symphonX™ Instruments for a specific surgical procedure, patient anatomy and/or operative site is at the physician’s discretion.
“This product line extension was developed in response to surgeon feedback,” said David Castiglioni, Vice President Sales of Fortimedix Surgical. “We have used these shorter instruments during cholecystectomy, inguinal hernia repair and several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform across surgical specialties. The launch of symphonX™ Instruments short signifies a substantial milestone as we continue to execute on our strategy to establish broad based market adoption of symphonX™ and elevate the standard of care in laparoscopy.”
For additional information or product specifications on symphonX™ Instruments short visit www.fortimedixsurgical.com.
About symphonX™
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.
About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for almost two decades. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit www.fortimedixsurgical.com
Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
For media inquiries, please contact: Fortimedix Surgical B.V., Monique Biermans, [email protected], +31 (0)6 24 676 376 Digital press release available at: www.fortimedixsurgical.com/news-events Lazar Partners, Chantal Beaudry, [email protected], or Amy Feldman, [email protected], +1 (212) 867-1762


Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 



